2[1]De Backer T L, Smedema J P, Carlier S G. Current management of primary pulmonary hypertention. Biol Drugs, 2001, 15:801-817.
3[2]Rich S, Kaufman E, Levy P. The effect of high doses of calcium-channel blockers on survival in primary pulmonary hypertension. N Engl J Med, 1992, 327:76-79.
4[3]Barst R J, Rubin L J, Long W A, et al. A comparison of continuous intravenous epoprostenol (prostacyclin) with conventional therapy for primary pulmonary hypertension. N Engl J Med, 1996, 334:296-302.
5[4]McLaughlin V, Genthner D, Panella M, et al. Reduction in pulmonary vascular resistance with long-term epoprostenol (prostacyclin) therapy in primary pulmonary hypertension. N Engl J Med, 1998, 338:273-277.
6[5]Shapiro S M, Oudiz R J, Cao T, et al. Primary pulmonary hypertension: improved long-term effects and survival with continuous intravenous epoprostenol infusion. J Am Coll Cardiol, 1997, 30:343-349.
7[6]Badesch D, Tapson V, McGoon M, et al.Continuous intravenous epoprostenol for pulmonary hypertension due to the scleroderma spectrum of disease. Ann Intern Med, 2000, 132:425-434.
8[7]Sebbag I, Rudski L G, Therrien J, et al. Effect of chronic infusion of epoprostenol on echocardiographic right ventricular myocardial performance index and its relation to clinical outcome in patients with primary pulmonary hypertension. Am J Cardiol, 2001, 88:1060-1063.
9[8]Simonneau G, Barst R J, Galie N, et al. Continuous subcutaneous infusion of treprostinil, a prostacyclin analogue, in patients with pulmonary arterial hypertension: A double-blind, randomized, placebo-controlled trial. Am J Respir Crit Care Med, 2002, 165:800-804.
10[9]Nagaya N, Uematsu M, Okano Y. Effect of orally active prostacyclin analogue on survival of outpatients with primary pulmonary hypertension. J Am Coll Cardiol, 1999, 34:1188-1192.
